Vetting SOP

This document describes the process Camden Medicals uses to review every product before it is listed for sale. It substantiates the “Clinically Vetted” framing of our private-label range.

What this covers

Every product on camdenmedicals.co.uk passes through this process before it is listed — both Camden’s own private-label range (SKU prefix NB-: Aurifera, Mycofera, Flexifera, and forthcoming Purifera and Clarifera) and any third-party products we resell. Existing products are re-reviewed annually or whenever a supplier changes.

Who carries out the vetting

A UK practitioner with both clinical and pharmacy training carries out the review and signs off the listing decision. We identify the reviewer by role rather than by name in public-facing material — personal credentials are kept off public surfaces but are verifiable on UK regulator registers if a regulator requests them.

This matches the framing in our Editorial Policy.

The six checks

1. Supplier vetting

  • Good Manufacturing Practice (GMP) certificate on file — date, scope, and certifying body recorded
  • Manufacturing origin verified (UK or EU)
  • Companies-House or equivalent register check on the supplier entity
  • BRCGS, ISO 22000, or equivalent third-party audit certificate where available
  • Recall and regulatory-action history checked — we do not source from suppliers with active or recent MHRA / FSA / EU RASFF enforcement

2. Certificate of Analysis (CoA) review

For every batch, we hold a CoA that establishes:

  • Identity of declared active ingredient(s)
  • Quantitative content vs label declaration
  • Heavy-metal limits (Pb, As, Cd, Hg) within JECFA / EU permitted limits
  • Microbiological limits per Ph. Eur. 5.1.4 or equivalent
  • Solvent residues (ICH Q3C) and pesticide residues (Reg. 396/2005) where applicable

3. Formulation review

  • Dose matched to the published evidence base where evidence exists — underdosed formulas are not listed
  • EFSA Article 13.1 cofactor check — UK-authorised health claims are referenced only where the product contains the EFSA-required minimum dose per recommended daily portion
  • Excipient audit — solvents, fillers, capsule shells, sweeteners reviewed for allergens and dietary suitability (vegan, gelatin, halal, kosher status declared accurately on the product page)

4. Interaction and contraindication screening

  • British National Formulary (BNF) interaction check for each active
  • Pregnancy and breastfeeding suitability per NHS and NICE guidance
  • Paediatric suitability per BNF for Children where the age range is broadened
  • Contraindications surfaced on the product detail page

5. Labelling and claims review

  • No therapeutic claims (treats, cures, prevents, or diagnoses any condition)
  • No medicinal claims that would bring the product within scope of the Human Medicines Regulations 2012
  • Health claims, where made, restricted to entries in the Great Britain Nutrition and Health Claims Register (Article 13.1 / 13.5 / 14)
  • “Pharmacy-grade” or similar quality framings used only where supplier GMP and CoA evidence support them

6. Sign-off and records

A signed dossier is held for every product covering all five preceding checks. Records are retained for the duration the product is listed plus seven years.

What “Clinically Vetted” means — and what it doesn’t

The “Clinically Vetted” framing on our private-label products refers to this six-step process — supplier, batch CoA, formulation, interactions, labelling, and recorded sign-off. It is not a claim that the products themselves are tested as pharmaceutical drugs in clinical trials, and it is not a substitute for professional medical advice. If you take prescribed medicines, are pregnant or breastfeeding, or have an existing condition, talk to your pharmacist or GP before starting any supplement.

Suspected side effects from any medicine or supplement can be reported to the MHRA via the Yellow Card scheme.

Regulatory framework this SOP defends

If our “Clinically Vetted” framing is challenged, this document is the evidence that the claim is process-backed rather than rhetorical. It substantiates Camden’s position under:

  • Consumer Protection from Unfair Trading Regulations 2008 (Trading Standards / Competition and Markets Authority)
  • CAP Code rule 12.1 (Advertising Standards Authority — proof of objective claims)
  • Human Medicines Regulations 2012 (Medicines and Healthcare products Regulatory Agency, where applicable)

How to raise a concern

If you believe a Camden Medicals product page, encyclopaedia entry, or health guide misrepresents an ingredient, dose, or claim, please contact us. We will review and, where the concern is substantiated, correct the page promptly with a dated change note.

Version

This document was last updated on 13 May 2026. Material changes will be noted here and dated.